Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study.
Diamant ThaҫiAndrea BauerRalph von KiedrowskiFlorian SchenckKonstantin ErtnerSophie MöllerAnja FaitMike BastianMatthias AugustinPublished in: Dermatology and therapy (2022)
Patients with moderate-to-severe AD present a long medical history, impaired quality of life, and high prevalence of co-existing type 2 inflammatory diseases. Dupilumab was used as a first-line systemic treatment in 38.6% of patients.